Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

10.0%

235 terminated/withdrawn out of 2354 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

25%

584 trials in Phase 3/4

Results Transparency

27%

510 of 1887 completed trials have results

Key Signals

81 recruiting510 with results186 terminated49 withdrawn

Enrollment Performance

Analytics

Phase 1
472(27.6%)
Phase 2
467(27.3%)
Phase 3
398(23.2%)
Phase 4
186(10.9%)
N/A
183(10.7%)
Early Phase 1
7(0.4%)
1713Total
Phase 1(472)
Phase 2(467)
Phase 3(398)
Phase 4(186)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2354)

Showing 20 of 2354 trials
NCT03970447Phase 2Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Role: collaborator

NCT05099172Phase 1Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Role: lead

NCT02016222Not ApplicableTerminated

Tear Analysis in the Diagnosis of Multiple Sclerosis

Role: collaborator

NCT07557147Not Yet Recruiting

Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor

Role: lead

NCT07640997Recruiting

Real-world Study of Aflibercept 8 mg in nAMD

Role: collaborator

NCT06854640Phase 1Recruiting

A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

Role: lead

NCT06800248Phase 3Not Yet Recruiting

Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections

Role: collaborator

NCT04879368Phase 3Completed

RegoNivo vs Standard of Care Chemotherapy in AGOC

Role: collaborator

NCT06914128Phase 1Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

Role: lead

NCT07582328Phase 2Completed

A Study to Learn More About How Well Oxymetazoline HCl 0.05% Nasal Gel Works and How Safe It Is in Healthy Adults

Role: lead

NCT07088458Not Yet Recruiting

An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A

Role: lead

NCT05705258Active Not Recruiting

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Role: lead

NCT07298044Phase 4Recruiting

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Role: lead

NCT04597125Phase 4Active Not Recruiting

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Role: lead

NCT06428825Phase 1Completed

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure

Role: lead

NCT06944522Phase 3Recruiting

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Role: collaborator

NCT07192952Phase 3Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

Role: lead

NCT07071961Phase 2Suspended

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Role: collaborator

NCT07566429Phase 2Not Yet Recruiting

A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)

Role: lead

NCT07176728Phase 1Completed

A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.

Role: lead